⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4860801 | 0.84 | GRM5 (0.46) | — | |
| SCHEMBL9093824 | 0.81 | GRM5 (0.43) | — | |
| SCHEMBL15870993 | 0.79 | GRM5 (0.68) | — | |
| SCHEMBL9794433 | 0.79 | — | — | |
| SCHEMBL737153 | 0.79 | — | — | |
| SCHEMBL9906037 | 0.79 | GRM5 (0.44) | — | |
| SCHEMBL4853827 | 0.79 | GRM5 (0.44) | — | |
| SCHEMBL9794373 | 0.79 | GRM5 (0.44) | — | |
| SCHEMBL9794361 | 0.79 | GRM5 (0.44) | — | |
| Iodide SCHEMBL9794472 | 0.77 | GRM5 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323991-A1 | TETRAHYDROPYRAN-BASED THIODISACCHARIDE MIMICS AS GALECTIN-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-21 | — | — | US | disclosed |
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
| EP-2285775-B1 | Lactams and their use in the treatment of inter alia ocular hypertension or baldness | ALLERGAN INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2121672-B1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2014-12-10 | — | — | EP | disclosed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8569349-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-7705001-B2 | Therapeutic substituted gamma lactams | ALLERGAN, INC (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090318449-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090286787-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090281104-A1 | Therapeutic Compounds | ALLERGAN, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009137345-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090270385-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270396-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009132093-A2 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090239867-A1 | THERAPEUTIC SUBSTITUTED GAMMA LACTAMS | ALLERGAN, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239858-A1 | THERAPEUTIC AMIDES | ALLERGAN, INC. (US) | 2009-09-24 | — | — | US | disclosed |